Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Profit After Tax (2020 - 2025)

SAB Biotherapeutics' Profit After Tax history spans 6 years, with the latest figure at -$16.9 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 47.97% year-over-year to -$16.9 million; the TTM value through Dec 2025 reached $13.3 million, up 138.92%, while the annual FY2025 figure was $13.3 million, 138.92% up from the prior year.
  • Profit After Tax reached -$16.9 million in Q4 2025 per SABSW's latest filing, down from $45.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $45.4 million in Q3 2025 to a low of -$22.9 million in Q4 2023.
  • Average Profit After Tax over 5 years is -$4.9 million, with a median of -$7.0 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: tumbled 128307.03% in 2021, then soared 539.11% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then crashed by 190.26% to -$22.9 million in 2023, then surged by 50.15% to -$11.4 million in 2024, then plummeted by 47.97% to -$16.9 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Profit After Tax are -$16.9 million (Q4 2025), $45.4 million (Q3 2025), and -$10.1 million (Q2 2025).